Evening Brief: Pharm Exec Unveils Global Top 50 Biopharma Companies with Four Chinese Firms Listed; Mindray Initiates Class II Recall of Over 4,000 AEDs

1. Pharm Exec Releases Top 50 Global Biopharmaceutical Companies, Four Chinese Pharmaceutical Enterprises Make the List

Top 50 Global Biopharmaceutical Companies Announced: Four Chinese Firms Make the List, Yunnan Baiyao Ranks Highest but Has Lowest R&D Spending and Does Not Disclose Key Drugs. Hengrui Medicine Drops in Ranking, R&D Spending Surges but Growth of Some Drugs Stalls. CSPC Pharmaceutical Falls Off the List. China Biologic Products and Shanghai Pharmaceuticals Show Steady Performance.

2. Over 4,000 External Defibrillators May Have Defects, Mindray Initiates Level Two Recall

Mindray Initiates Voluntary Recall of 4,483 Semi-Automatic and Automatic External Defibrillators from Specific Batches Due to Potential Functional Configuration Issues; No Adverse Event Reports Received. Mindray has conducted multiple product recalls in recent years, consistently taking proactive measures to prevent potential issues. This recall is expected to have no impact on the company's daily operations.

3. 12.5 Billion, Haier Expands Its Medical Territory

Haier Group, through its wholly-owned subsidiary Haiyingkang, acquired 20% of Shanghai RAAS for 12.5 billion yuan, becoming its controlling shareholder, further expanding Haier's presence in the healthcare sector. Previously, Haier already owned two listed companies, Yingcare Life and Haier Biomedical, and this acquisition will allow Haier to deeply integrate into the healthcare industry.

4. Cash in 1.4 Billion, Fosun Pharmaceutical's Investment in India Pays Off Big Time

Fosun Pharmaceutical Gains Approximately 1.4 Billion RMB from Selling Part of Its Stake in Gland Pharma, Maintaining Controlling Interest in the Indian Generic Drug Company

5. Gracell Selected for Annual List of Most Innovative Companies in Biopharmaceuticals, Honored with "Starlight Award"

Gracell Named the Most Innovative Company in Biopharmaceuticals, Developing Cell Therapies to Address Industry Challenges Such as High Costs and Inefficiency of CAR-T Therapies.

6. DK Medtech Completes Over Hundreds of Millions of Yuan in E-Round Financing: Developing More Than Ten Types of Balloons, Covering Almost All Vascular Intervention Fields

DK Medtech Completes Hundreds of Millions of Yuan in Series E Financing, Led by Legend Capital and Qiming Venture Partners; Funds to Strengthen Manufacturing, Commercialization, and Overseas Market Expansion